<b>Cut Slides:</b> H&E slide (required) plus 6 unstained slides cut at 4-5 microns.<br>
<b>Note for Tech Only clients:</b> Please circle H&E slide.
ALK (2p23)<br>
TP63 (3q28)<br>
TBL1XR1/TP63 [inv(3)(q26q28)]<br>
DUSP22-IRF4 (6p25.3)<br><br>
Testing Scheme: TP63 (3q28) and TBL1XR1/TP63 [inv(3)(q26q28)] are performed together and reported as co-dependent for the result and interpretation of TP63 rearrangement status. <br><br>Test Customization: Tech Only clients may order probes individually.</p>
The ALCL FISH Panel is used for the detection of recurrent chromosome abnormalities observed in patients with anaplastic large cell lymphoma (ALCL) which may classify those patients into specific risk groups. This panel includes ALK (2p23) rearrangement testing. Patients with ALK-positive ALCL have a favorable prognosis compared to ALK-negative ALCL patients. This panel also includes two assays to detect TP63 rearrangements. Rearrangements of the TP63 gene encoding p63 fusion defines a subset of ALK-negative ALCL cases and are associated with aggressive course and poor outcome as compared to peripheral T-cell lymphoma without these rearrangements.
The TBL1XR1/TP63 fusion [inv(3)] has also been reported in rare cases of peripheral T-cell lymphoma NOS, mycosis fungoides, diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. This panel also includes the DUSP22-IRF4 rearrangement test which has been reported in CD30-positive, ALK-negative ALCL and is associated with favorable clinical outcome. DUSP22-IRF4 rearrangements have been also reported in patients with lymphomatoid papulosis (LyP).